Guggenheim lowered the firm’s price target on Acadia Healthcare (ACHC) to $27 from $29 and keeps a Buy rating on the shares following the company’s Q3 report and 2025 guidance. While the firm continues to hold a favorable view around the long-term behavioral health thesis and Acadia’s positioning, it says near-term execution “remains paramount” for greater multiple expansion.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare’s Earnings Call: Mixed Sentiments and Strategic Moves
- Optimistic Buy Rating for Acadia Healthcare Amid Strategic Growth Initiatives
- Acadia Healthcare price target lowered to $22 from $25 at Cantor Fitzgerald
- Acadia Healthcare price target lowered to $28 from $31 at UBS
- Acadia Healthcare Reports Q3 Revenue Growth Amid Challenges